Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Vela Technologies Plc LSE:VELA London Ordinary Share GB00BYZ9XC29 ORD 0.01P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 0.0825 0.00 00:00:00
Bid Price Offer Price High Price Low Price Open Price
0.08 0.085
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Media -0.16 -0.02 10
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 0.0825 GBX

Vela Technologies (VELA) Latest News (1)

More Vela Technologies News
Vela Technologies Investors    Vela Technologies Takeover Rumours

Vela Technologies (VELA) Discussions and Chat

Vela Technologies Forums and Chat

Date Time Title Posts
21/1/202120:50Vela Technologies5,555
26/2/202021:25Podcast On VELA4

Add a New Thread

Vela Technologies (VELA) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-01-21 17:07:540.084,000,0003,300.00O
2021-01-21 16:23:500.081,469,1071,234.05O
2021-01-21 16:22:330.0834,41629.22O
2021-01-21 16:06:260.08769,008639.05O
2021-01-21 16:02:330.081,190,4761,000.00O
View all Vela Technologies trades in real-time

Vela Technologies (VELA) Top Chat Posts

DateSubject
21/1/2021
08:20
Vela Technologies Daily Update: Vela Technologies Plc is listed in the Media sector of the London Stock Exchange with ticker VELA. The last closing price for Vela Technologies was 0.08p.
Vela Technologies Plc has a 4 week average price of 0.06p and a 12 week average price of 0.06p.
The 1 year high share price is 0.19p while the 1 year low share price is currently 0.03p.
There are currently 12,074,071,417 shares in issue and the average daily traded volume is 227,507,223 shares. The market capitalisation of Vela Technologies Plc is £9,961,108.92.
21/1/2021
20:50
bapodra_investments: Vela has a minority shareholding in Resolve and a stake in WeShop. Disruptive Tech is in wind down. BlockchainK2 could be a hidden gem in Vela's portfolio. I must admit I was focussing on Argo's share price action but it seems like BlockchainK2 could be a huge blockchain company in the years to come and Vela have got in early so it could prove to be extremely profitable. This is going to require patience and I am so glad I got my average down by adding at 0.08p.
21/1/2021
12:07
bapodra_investments: I agree dennisbergkamp. Vela should have kept Argo but my guess is they needed to raise capital and their Argo equity stake was more in demand and they could receive capital quicker than any of their other investments hence why they sort of were forced due to circumstances in selling their Argo stake. We cannot go back in the past and what's done is done but I agree with you. Vela's share price would have been higher than current levels. Imagine having Mode and Argo in Vela's portfolio? I think more substantial news is required on BlockchainK2 and more of a 'roadmap' is required.
21/1/2021
11:55
bapodra_investments: Looking at the Vela chart it seems to me that most of the downside is priced in already. So the upside potential now outweighs the downside potential. Some of the other shares have already seen humungous moves but Vela has not so I agree with Rebel in the sense that it is better to get in at these low prices before any potential monster move occurs to maximise gains. To counter that one could argue that Vela shares are low for a reason. I think severe dilution has not helped and some poor previous management decisions. We now have a new leader so we need to give him the time over the coming 12 months and then see where Vela is. I think current prices are worth investing in from a risk/reward basis but there are no guarantees of course. We should only invest capital that we are prepared to lose or do not require for our day to day lives. Investing presents its owns risks and we will all have different risk management strategies to deal with the risks in our own portfolios. The fact that Vela's share price has not been declining recently and seems to be holding in the current range suggests to me that there are not that many sellers right now. We need more buyers and they are likely to come on news flow here. I think Vela is a share that will move on positive news flow.
20/1/2021
18:30
bapodra_investments: I have just added to my position today which has considerably brought down my average price considering I invested in Vela a few years ago at a much higher price. As a result my losses have reduced though my exposure to Vela has increased. I was considering investing in Mode Global Holdings PLC but it is back to its IPO price and I fear it may have to raise further capital which could lead to dilution and therefore added to my Vela position instead. Vela has invested £250,000 in Mode which gives me an indirect exposure to Mode and slightly de-risks my investment as Vela is invested in other businesses too. So some diversification. Does anyone know what Vela's plans are with North Peak Resources? I am not sure how North Peak fits into Disruptive Technology but do you think they are looking to sell their stake? There has been no recent update on BlockchainK2. I must admit this investment has been disappointing when you compare how Argo have performed and are doing right now. Also the lives of Riot and Hive have done rather well recently. I would like to see Vela sell some deadwood and replace with some new fresh investment opportunities like Mode. I am sure that is what they are currently working on with possible announcements to follow over the coming months.
03/1/2021
12:00
cjohn: So Vela has invested £2.35m in the Arcadia trial. This gives it an 8% interest in any returns to St George Street Capital in excess of £19.2m, after deduction of sums payable to the major pharmaceutical company and certain funders, and provision for taxation. So to calculate what level of return to SGS produces a profit to Vela: 1. £2.35 divided by 0.08 is £29.375m. 2. £29.375m + £19.2m is £48.575m. 3.We now need to add the sums payable to the major pharmaceutical company and taxation. Taxation at 20% to simplify. (There will be tax breaks for research, I think). So add another £9.5m which makes about £58m. Let's say, at this level of return to SGS, an additional £25m goes to the major pharmaceutical company. (Btw nowhere does it say that this company is Astra. What difference would it make if it was? None whatsoever. It's completely immaterial whether it's Astra or another company.) So for Vela to break even on its £2.35 million investment in the trial, SGS needs to get a return of about £83m. Next question: what are the odds of SGS making this return? 1. What are the odds of the phase two trial failing? as a rule of thumb around a third of drugs that enter phase two trials fail. So a 0.33 chance of zero return. 2. Let's say the drug gets through phase 2, but doesn't look promising enough to attract a buyer at that point. Again a rough rule of thumb would be about 30% fall into this category. So there's a roughly 63% chance that the results are unsatisfactory or won't attract a new buyer or the Major Pharmaceutical Company to re-buy full control of its asset. A % of the 30% in this second category WILL go on to phase three trails, but we can assume Vela's participation will be heavily diluted. 3. It's very difficult to estimate what the return will be to SGS, if the drug does have a successful 2nd phase trial that attracts a buyer. So Vela have, in effect, bought an option for £2.35m. In 63% of cases, we can assume the option expires worthless.(In reality, in a very few of such cases, Vela might still have some return: see point 2.) In the other 37%, we might hope for a significant uplift on the investment. Unfortunately, in some of those 37% of cases, the uplift will either produce no gain for Vela (i.e. SGS bought out at less than £83m or at only a modest amount above £83m.) On the other hand, in a significant percentage of cases - say 20%, the return to Vela could be many times their current market cap. Overall, I think it's a reasonable wager to make. It could be transformational, but the odds are against it. I have no position here.
14/12/2020
07:21
bapodra_investments: Gostaa - You are absolutely right. I fully agree with you. Rebel - If that is true brilliant. Maybe I have been rushing through the website. It would be so helpful if you could just copy and past that sentence or paragraph so that we all can see the context. I have provided my evidence, can you? You may be right about me struggling to do my due diligence. In fact I hope you are right. However, I have shared what I could see. Can you share your due diligence? Lack of credible evidence is extremely disconcerting. I am being open and honest. I could not find the things that you some are posting on this forum. If it is true just copy and paste/share with all. Unfortunately I have invested. I wish I had not but I certainly would not invest today in this company. However, I am currently a holder so will continue to keep an eye on this. The share price action over the past 2-3 years has been appalling. Even after this apparent Astra link the share price performance is appalling. Price action is king and trends are important. I see neither in Vela's chart that is encouraging. I am happy to be wrong but that would reply on luck and hope which in my opinion is all any investors can do here. Hope and Luck.
13/12/2020
17:06
bapodra_investments: Thank you Gostaa but there is no mention of AstraZeneca. It is a trial which we all know about from the RNS. Ohh my... It states the following on the Vela Technologies PLC website which by does not necessarily mean that any AstraZeneca vaccine will have a positive impact on the share price of Vela. ----------------------------------------------------------------------------------------St George Street Capital Limited St George Street (SGS) is a UK-based medical-charity led by a group of highly decorated academics and ex-pharma executives formed to deliver much needed treatments to patients. SGS’s strategy is to take clinical-ready assets from pharmaceutical companies and to progress them through Phase II medical trials, before licensing them on for Phase III trials and commercialisation in order to create a return for investors and the charity alike. Under an agreement entered into in August 2019, SGS has acquired the right to develop and commercialise two assets from a major global pharmaceutical company, one of which includes the licence to a drug that could be beneficial to diabetic patients suffering with COVID-19 (the “Asset”). Diabetics have significantly higher mortality compared with non-diabetic patients in COVID-19 and in clinical studies this drug, SGS002, has been found to be safe in almost 1,000 patients with diabetes and has a blood glucose lowering effect for four months. Blood glucose control has been proposed as a key factor in reducing complications from COVID-19 in diabetics. SGS is proposing to recruit up to 150 patients for a clinical trial to test SGS002, which it estimates will take 5 months to complete. SGS is working to a compressed timescale given the urgency of the COVID-19 situation and anticipates reaching clinical stage in early May 2021. Vela paid £2.35m for an 8% economic interest. Following the transaction SGS holds 9.37% of Vela ---------------------------------------------------------------------------------------- If anyone actually has any credible (evidence based) material by all means copy and paste it here but otherwise I am just reading assumptions and inferences without any substance.
13/12/2020
11:53
bapodra_investments: I am not aware of any link between Vela Diagnostics and Vela Technologies PLC. They are two different companies albeit both involved in COVID. Vela has a very small interest whereas Vela Diagnostics is heavily involved in this area. Where is the evidence that Vela is invested in anything that relates to AstraZeneca and the vaccine which will lead to any significant revenue for Vela? I appreciate the recent RNS with the diabetes angle and recent investment but it is very vague with any lack of detail or confirmation of anything in relation to some of the posts I am seeing here on this forum. When I say evidence I mean a credible document, article or something which can be shared here for all that confirms any significant link between Vela Technologies PLC and AstraZeneca? Vela Diagnostics is nothing to do with Vela Technologies PLC but I am happy to be proven wrong incase I have missed it whilst conducting a basic check on the internet. I would like nothing more than this to be true so apologies if I have missed it.
07/11/2020
08:45
under the radar: This tranche of warrents are nearly cleared . There was 4.481b warrents (26th Aug rns) 16th Sep 1.4b converted 29th Sep 107m converted 5th Nov 336m converted So still another 2.6b to be converted but as you can see they are not converting them all of the time, only as and when they are needed. It’s also worth mentioning that the share price has climbed from 0.5p - 0.1325p since they were issued so they have not had a adverse effect on the share price. It should be seen as a positive thing because they have money for investments whenever they need it (which will push the share price up to higher highs,as it has done already) Nothing to be worried about at all imho Another investment rns must be imminent!
05/11/2020
23:20
under the radar: This tranche of warrents are nearly cleared . There was 4.481b warrents (26th Aug rns) 16th Sep 1.4b converted 29th Sep 107m converted 5th Nov 336m converted So still another 2.6b to be converted but as you can see they are not converting them all of the time, only as and when they are needed. It’s also worth mentioning that the share price has climbed from 0.5p - 0.1325p since they were issued so they have not had a adverse effect on the share price. It should be seen as a positive thing because they have money for investments whenever they need it (which will push the share price up to higher highs,as it has done already) Nothing to be worried about at all imho
Vela Technologies share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
VELA
Vela Techn..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210122 07:30:13